Department of Thoracic Medicine, Hunan Cancer Hospital/ The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Department of Clinical Spiritual Care, Hunan Cancer Hospital/ The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CHINA
BMJ Support Palliat Care. 2024 Jan 8;13(e3):e1084-e1092. doi: 10.1136/bmjspcare-2021-003290.
The distress is associated with the life quality and prognosis of patients with lung cancer. Distress thermometer (DT) has been widely recommended for distress screening. This study was conducted to summarise the positive rate of distress in patients with lung cancer using DT screenings.
The PubMed, Embase, PsyclNFO and Cochrane Library databases were comprehensively searched to identify all eligible studies published before 31 December 2021. Studies were eligible if they were published in peer-reviewed literature and evaluated distress levels by DT.
Ten eligible studies, including a total of 2111 patients, were included in this analysis, and their methodological quality was moderate. The pooled positive rate of distress in patients with lung cancer was 49.04% (95% CI 41.51% to 56.60%). The subgroup analysis revealed that the distress positive rate was significantly different (p<0.05) across North America, Europe and China with values of 53.33% (95% CI 45.22% to 61.37%), 43.81% (95% CI 31.57% to 56.43%) and 38.57% (95% CI 33.89% to 43.41%), respectively. Moreover, the distress positive rate was significantly different between men and women (p<0.05). Additionally, in terms of histological type, clinical tumour, node, metastasis stage, previous treatment and DT threshold, the distress positive rate had no significant differences. No significant publication bias was identified by Begg's funnel plot and Egger's test.
The summarised distress positive rate was high and was significantly different according to gender and region. DT screening should be recommended for routine clinical practice and more attention should be given towards distress management.
痛苦与肺癌患者的生活质量和预后相关。痛苦温度计(DT)已被广泛推荐用于痛苦筛查。本研究旨在总结使用 DT 筛查评估肺癌患者痛苦的阳性率。
全面检索 PubMed、Embase、PsyclNFO 和 Cochrane Library 数据库,以确定截至 2021 年 12 月 31 日发表的所有合格研究。如果研究发表在同行评议文献中,并使用 DT 评估痛苦水平,则认为该研究合格。
纳入了 10 项合格研究,共计 2111 例患者,其方法学质量为中等。肺癌患者的痛苦阳性率为 49.04%(95%CI 41.51%至 56.60%)。亚组分析显示,北美、欧洲和中国的痛苦阳性率差异有统计学意义(p<0.05),分别为 53.33%(95%CI 45.22%至 61.37%)、43.81%(95%CI 31.57%至 56.43%)和 38.57%(95%CI 33.89%至 43.41%)。此外,男性和女性之间的痛苦阳性率也有显著差异(p<0.05)。此外,在组织学类型、临床肿瘤、淋巴结、转移分期、既往治疗和 DT 阈值方面,痛苦阳性率没有显著差异。Begg 漏斗图和 Egger 检验未发现明显的发表偏倚。
总结的痛苦阳性率较高,且根据性别和地区存在显著差异。DT 筛查应在常规临床实践中推荐,并应更加关注痛苦管理。